Tim-3 Antibodies Block Immune Suppression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for cancer and immune-related disorders face challenges due to the immune suppressive function of Tim-3, which limits the effectiveness of treatments targeting other immune checkpoints like PD-1.

Innovation Solution

Development of monoclonal antibodies or antigen-binding fragments that specifically bind to the IgV domain or IgV mucin-stalk of human Tim-3, inhibiting its immune suppressive functions and enhancing T cell responses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If Tim-3 is left untargeted, then existing immune checkpoint therapies can be used, but their effectiveness is limited by Tim-3-mediated immune suppression

Engineering Contradiction:

Improveeffectiveness of immune checkpoint therapyVSAvoidimmune suppression

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent introduces monoclonal antibodies as intermediary molecules that specifically bind to Tim-3 receptor on T cells and Tim-3 ligands on antigen-presenting cells, blocking the harmful Tim-3-mediated immune suppression pathway while allowing other immune checkpoint therapies to function

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention converts the harmful immune suppressive function of Tim-3 into a beneficial therapeutic target by developing antibodies that block Tim-3, thereby transforming the pathological immune suppression into an opportunity for enhancing anti-tumor immune responses

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

2Reliability

If multiple immune checkpoints are targeted simultaneously, then comprehensive immune suppression can be overcome, but treatment complexity increases

Engineering Contradiction:

Improvecomprehensive immune suppression controlVSAvoidtreatment regimen complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The developed monoclonal antibodies exhibit multi-functionality by simultaneously blocking Tim-3 interactions and potentially synergizing with other immune checkpoint blockers (PD-1, CTLA-4), providing comprehensive immune suppression control through a single therapeutic agent

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250034248A1Monoclonal antibodies against human tim-3

Publication Date: 2025.01.30 ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIV

AI summary

Provided are anti-human Tim-3 IgV domain-specific antibodies and fragments thereof, as well as methods of use employing such antibodies and/or fragments.